1
|
Koehl V, Bhatt O, Zeschke S, Kröger N, Triviai I. PS1448 LIN-CD133+CD34+CD41+ HSPC REPRESENT A MEGAKARYOCYTE-PRIMED NEOPLASTIC FRACTION IN MPN PATIENTS WITH MYELOFIBROSIS. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000564056.66360.ba] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
2
|
Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N. Impact of molecular residual disease post allografting in myelofibrosis patients. Bone Marrow Transplant 2017; 52:1526-1529. [PMID: 28714945 DOI: 10.1038/bmt.2017.157] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Revised: 03/09/2017] [Accepted: 04/29/2017] [Indexed: 01/13/2023]
Abstract
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (n=101), thrombopoietin receptor gene (MPL) (n=4) or calreticulin (CALR) (n=31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI): 50-70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18-34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P<0.001) and 70% vs 10%, P<0.001, respectively) irrespectively of the underlying mutation. In a multivariate analysis, high-risk diseases status (hazard ratio (HR) 2.5; 95% CI: 1.18-5.25, P=0.016) and detectable MRD at day 180 (HR 8.36, 95% CI: 2.76-25.30, P<0.001) were significant factors for a higher risk of relapse.
Collapse
Affiliation(s)
- C Wolschke
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Badbaran
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Zabelina
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Christopeit
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Ayuk
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - I Triviai
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Zander
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Alchalby
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - U Bacher
- Department of Hematology and Oncology, University Hospital Göttingen, Göttingen, Germany
| | - B Fehse
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - N Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
3
|
Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, Triviai I, Alchalby H, Kröger N, Kreipe H. SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. Leukemia 2014; 29:253-5. [PMID: 25231745 PMCID: PMC4287655 DOI: 10.1038/leu.2014.277] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- S Bartels
- Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany
| | - U Lehmann
- Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany
| | - G Büsche
- Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany
| | - J Schlue
- Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany
| | - M Mozer
- Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany
| | - J Stadler
- Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany
| | - I Triviai
- Department of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany
| | - H Alchalby
- Department of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany
| | - N Kröger
- Department of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany
| | - H Kreipe
- Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany
| |
Collapse
|